CRVS
HealthcareCorvus Pharmaceuticals, Inc.
$6.79
$-0.53 (-7.24%)
Jan 5, 2026
Price History (1Y)
Analysis
Corvus Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $507.09 million and 31 employees. The company's financial health is marked by unprofitability, with gross margin, operating margin, and profit margin all at 0.0%. Net income (TTM) stands at -$15,075,000, while EBITDA is -$38,760,000. Free cash flow is also negative, amounting to -$58,109,876. However, the company has a significant amount of cash on hand, totaling $65.69 million, and relatively low debt of $1.01 million. Corvus Pharmaceuticals' valuation metrics are notable for their negative values, including a forward P/E ratio of -11.61 and an EV/EBITDA ratio of -12.44. The company's return on equity is -$35.8%, and its return on assets is -$34.9%. The debt to equity ratio is 1.41, while the current ratio is 8.29.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $507.09M
- P/E Ratio
- N/A
- 52-Week High
- $9.60
- 52-Week Low
- $2.54
- Avg Volume
- 1.25M
- Beta
- 0.69
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 31